Chyavanprash: A Multimodal Approach to COVID-19 Management
International Journal of Pathogen Research,
The word Chyavanprash (CP) comprises of ‘Chyawan’ and ‘Prasha’. Chyavan represents ‘degenerative change’ and Prasha symbolises a drug. Enhancement of immunity and longevity of life were the main reasons for which CP was consumed since ancient times. CP has about 50 herbs, spices and minerals along with a range of pharmacological activities on almost all organ systems of the human body.
COVID-19 actually means coronavirus disease 2019. COVID-19 targets and affects multiple organs like lungs, heart, kidney etc, thus increasing the mortality and morbidity rates. The medication cost and side effects have made the allopathic system of medicine the least sought after. The rapid spread rate of the infection has urged mankind to look at alternative remedies to fight the novel coronavirus.
AYUSH is a government organisation under the Ministry of Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homoeopathy which aims to promote indigenous alternative medicine systems in India. AYUSH recommends various measures to fight the novel coronavirus infection.
Chyavanprash is one such important formulation proposed by the AYUSH for COVID-19. The purpose of our review is to highlight the constituents and pharmacological activities of CP in the prophylaxis, manage and treatment of COVID-19 by collecting and compiling the published research on COVID-19. The review also focuses on understanding the mechanism behind the multimodal activity of CP. References relevant to our topic were screened based on relevance to our topic.
- alternative medicine systems
How to Cite
Rizzo P, Vieceli Dalla Sega F, Fortini F, Marracino L, Rapezzi C, Ferrari R. COVID-19 in the heart and the lungs: could we “Notch” the inflammatory storm? Basic Research in Cardiology. 2020;115(3):31.
Tillu G, Chaturvedi S, Chopra A, Patwardhan B. Public Health Approach of Ayurveda and Yoga for COVID-19 Prophylaxis. Journal of Alternative and Complementary Medicine. 2020;26(5):360–364.
Ministry of AYUSH. Ayurveda’s immunity boosting measures for self care during COVID 19 crisis; 2020.
Sharma R, Martins N, Kuca K, Chaudhary A, Kabra A, Rao MM, Prajapati PK. Chyawanprash: A traditional indian bioactive health supplement. Biomolecules. 2019;9(5).
Ojha JK, Khanna NN, Bajpay HS, Sharma N. A clinical study on Chyavanprash as an adjuvant in the treatment of pulmonary tuberculosis. J. Res. Ind. Med. 1975;10:11–14.
Ojha JK, Bajpai HS, Sharma PV, Khanna NN, Shukla PK, Sharma TN. Chyavanprash as an anabolic agent; An experimental study (preliminary work). J. Res. Ind. Med. 1973;8:11–14.
Debnath PK, Chattopadhyay J, Mitra A, Adhikari A, Alam MS, Bandopadhyay SK, Hazra J. Adjunct therapy of Ayurvedic medicine with anti tubercular drugs on the therapeutic management of pulmonary tuberculosis. Journal of Ayurveda and Integrative Medicine. 2012;3(3):141–149.
Sharma PV, Dravayagun Vigyan. Chaukhamba Bharati Academy. 2003b;II.
Datiya TD, India, undefined, &, undefined. (n.d.). Shree Sharma Ayurved Mandir; 1979.
Sharma PV. Classical uses of medicinal plants. In Haridas Ayurveda (Issue 4); 1996.
Sur TK, Pandit S, Mukherjee R, Pramanik T, Debnath PK, Bandyopadhyay SK, Bhattacharyya D. Effect of Sonachandi Chyawanprash and Chyawanprash Plus--two herbal formulations on immunomodulation. Nepal Medical College Journal : NMCJ. 2004;6(2):126–128. Available:https://europepmc.org/article/med/16295744
Bhattacharya SK, Bhattacharya D, Sairam K, Ghosal S. Effect of bioactive tannoid principles of Emblica officinalis on ischemia-reperfusion-induced oxidative stress in rat heart. In Phytomedicine. Urban und Fischer Verlag Jena. 2002;9(2):171–174.
Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: How are they linked? In Free Radical Biology and Medicine. 2010;49(11);1603–1616. NIH Public Access.
Govindarajan R, Vijayakumar M, Pushpangadan P. Antioxidant approach to disease management and the role of “Rasayana” herbs of Ayurveda. Journal of Ethnopharmacology, 2005a;99(2):165–178.
Jose JK, Kuttan R. Antioxidant Activity of Emblica officinalis. Journal of Clinical Biochemistry and Nutrition. 1995;19(2):63–70.
Middha Anil, Purohit Suresh. Determination Of Free Radical Scavenging Activity In Herbal Supplement: Chyawanprash | Insight Medical Publishing. International Journal of Drug Development and Research. 2011;3(1): 328–333.
Zheng YY. Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. In Nature Reviews Cardiology. 2020;17(5);259–260. Nature Research.
Manjunatha S, Jaryal AK, Bijlani RL, Sachdeva U, SKG. Effect of Chyawanprash and vitamin C on glucose tolerance and lipoprotein profile. Indian Journal of Physiological Pharmacology. 2001;45(1):71–79.
Thakur CP, Thakur B, Singh S, Sinha PK, Sinha SK. The Ayurvedic medicines Haritaki, Amla and Bahira reduce cholesterol-induced atherosclerosis in rabbits. International Journal of Cardiology. 1988;21(2):167–175.
Hashem-Dabaghian F, Ziaee M, Ghaffari S, Nabati F, Kianbakht S. A systematic review on the cardiovascular pharmacology of Emblica officinalis Gaertn. Journal of Cardiovascular and Thoracic Research. 2018;10(3):118–128.
Trikam YD. Shree Sharma Ayurved Mandir. 1979b;465.
Trikam YD. Shree Sharma Ayurved Mandir: Datiya (Y. D. Trikam (Ed.)); 1979a.
Ernst E. Scientific Basis for Ayurvedic Therapies. Focus on Alternative and Complementary Therapies. 2010;9(3): 243–243.
Govindarajan R, Vijayakumar M, Pushpangadan P. Antioxidant approach to disease management and the role of “Rasayana” herbs of Ayurveda. In Journal of Ethnopharmacology. J Ethnopharmacol. 2005b;99(2):165–178.
Kumar A, Rinwa P, Kaur P. Chyawanprash A wonder Indian Rasayana from Ayurveda to Modern Age | earthjournals publisher - Academia.edu. Modern Age. Crit. Rev. Pharm. Sci. 2012;1:1–8.
Gogate VM. Emblica officinalis. In Drvyaguna Vigyan (1st ed); 1962.
Characterizing the antioxidant activity of amla (Phyllanthus emblica) extract. Current Science. 2001;81:185–190.
COVID Research Updates: Dense cities should brace for long coronavirus outbreaks. (n.d.); 2020.
Diabetes and COVID-19. (n.d.); 2021.
Guidelines for Clinical Trials on AYUSH interventions for COVID-19 – by ID-AYUSH-R&D Task Force. (n.d.).
Sharma PV, Dravayagun Vigyan. Chaukhamba Bharati Academy. 2003a;II.
Abstract View: 53 times
PDF Download: 16 times